Our results show that Cbl-b inhibitors, by inducing Notch1-dependent CD8+ T-cells responses, have a promising potential as anti-cancer single-agents and as combinatorial immunotherapy with checkpoint inhibitors. The gene discussed is CBLB; the disease is cancer.